Ocugen (OCGN) Proxy filing summary

Executive summary

• Achieved key milestones, including raising capital to pay off high-interest debt and extending cash runway.

• Secured a licensing partnership for OCU400 in the Middle East and North Africa, validating the gene therapy platform and regional strategy.

• Advanced regulatory discussions for the Phase 3 study of the Geographic Atrophy program (OCU410).

• Plans for three BLA submissions by 2028, aiming to become a commercial-stage biotechnology company.

• Forward-looking statements highlight growth strategies, financing, and partnership expectations, subject to risks and uncertainties.

Voting matters and shareholder proposals

• Proposal 1: Approve an amendment to increase authorized common stock by 250,000,000 shares.

• Proposal 2: Approve adjournment of the Special Meeting to solicit additional proxies if needed.

• Board recommends voting FOR both proposals.

• Voting is open to shareholders of record as of July 27, 2026.

Board of directors and corporate governance

• Board unanimously approved the proposed amendment to the Charter, subject to shareholder approval.

• Board may abandon the amendment at any time prior to filing, even after shareholder approval.

• No cumulative voting for directors, making board replacement more difficult.

• Stockholders can communicate with the Board via the Corporate Secretary.